#United States #Vaccination #Emeryville #Hepatitis B #Dynavax

Dynavax Survey Highlights Public Misunderstanding of Hepatitis B

In a recent survey conducted by Dynavax Technologies, significant gaps in public understanding regarding hepatitis B and its potential health consequences have been revealed. Approximately 54% of American adults expressed little concern about contracting hepatitis B, largely due to a lack of awareness about the risks associated with the virus. This survey coincided with Hepatitis Awareness Month, underscoring the urgent need for enhanced public education campaigns surrounding this viral illness.

Key Findings from the Survey

The results from the Harris Poll survey indicated that over half of American adults are unaware that chronic hepatitis B can lead to severe liver diseases, including cirrhosis and liver cancer. Alarmingly, half of those surveyed did not recognize that anyone could be susceptible to the hepatitis B virus. Among those who felt unconcerned, common reasons included a belief that they were not at risk, having never experienced symptoms, or lacking discussions about hepatitis B with their healthcare providers.

The CDC's Recommendations

The Centers for Disease Control and Prevention (CDC) has established guidelines recommending that all eligible adults aged 19 and above receive the hepatitis B vaccine. Despite these recommendations, vaccination rates among U.S. adults remain unsatisfactorily low, with more than 130 million adults still unprotected. According to health officials, hepatitis B vaccination is particularly critical for adults aged 19 to 59, as well as for those aged 60 and older who exhibit risk factors.

The Importance of Education

Rob Janssen, Chief Medical Officer at Dynavax, emphasized the critical necessity for ongoing education about hepatitis B, stating, "The results from this survey highlight the need for comprehensive public education and information dissemination on preventing hepatitis B. As we mark Hepatitis Awareness Month, these findings reaffirm our commitment to collaborating with healthcare professionals to inform Americans about the significant public health risks posed by this virus."

Chronic hepatitis B can result in devastating outcomes. Yet, the survey revealed that over fifty percent of respondents did not know it could lead to liver cancer. Only about one in three individuals knew how the virus spreads, and a mere 20% of participants correctly recognized that the hepatitis B vaccine can prevent liver infections.

Dr. Chari A. Cohen, President of the Hepatitis B Foundation, noted that these insights are crucial for forming a broader understanding of this incurable condition. Raising awareness about the need for preventive measures through vaccination is vital.

Next Steps and Community Engagement

Dynavax is planning to host a LinkedIn Live event on May 27, 2025, featuring a panel of hepatitis B experts who will discuss the survey results, existing educational gaps, and strategies to promote conversations about vaccination-driven prevention strategies. Individuals interested in joining this discussion can visit www.hepBaware.com for further details and registration to the LinkedIn Live event.

This survey's findings not only underscore the necessity for enhanced public awareness but also shine a light on the widespread misconceptions surrounding hepatitis B and its vaccine. Improving education and outreach is essential in combating this public health challenge effectively.